Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors

Inclusion Criteria: * Patients must have histological or serological proof of metastatic germ cell neoplasm (gonadal or extragonadal primary) with disease not amenable to cure with either surgery or chemotherapy; patients with seminoma and nonseminoma are eligible, as are women with ovarian germ cell tumors * Patients must have evidence of recurrent or metastatic carcinoma by one or more of the criteria specified in the protocol * Patients must have received initial cisplatin based combination therapy (such as bleomycin, etoposide and cisplatin \[BEP\], etoposide and cisplatin \[EP\], VP-16 plus ifosfamide plus cisplatin \[VIP\] or similar regimens) AND demonstrated progression following the administration of at least one 'salvage' regimen for advanced germ cell neoplasm (such as high dose chemotherapy, paclitaxel/ifosfamide/cisplatin \[TIP\] or vinblastine, ifosfamide and cisplatin \[VeIP\]) * Patients must have documented "failure" of prior therapy as defined in the protocol * Patients are eligible after first line platinum based chemotherapy if their disease has relapsed and they have primary mediastinal non seminomatous germ cell tumor (PMNSGCT) or late relapse (\> 2 years) not amenable to surgical resection * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Laboratory test results must be within ranges established in the protocol * Potential subject must have the ability to understand (as judged by the treating physician) and willingness to provi…